Hepatology最新文献

筛选
英文 中文
Real-world evidence for factors associated with maintenance treatment practices among US adults with autoimmune hepatitis. 美国成人自身免疫性肝炎患者维持治疗方法相关因素的现实证据。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-02-01 Epub Date: 2024-06-12 DOI: 10.1097/HEP.0000000000000961
Therese Bittermann, Lina Yagan, Ranganath G Kathawate, Ethan M Weinberg, Eliot G Peyster, James D Lewis, Cynthia Levy, David S Goldberg
{"title":"Real-world evidence for factors associated with maintenance treatment practices among US adults with autoimmune hepatitis.","authors":"Therese Bittermann, Lina Yagan, Ranganath G Kathawate, Ethan M Weinberg, Eliot G Peyster, James D Lewis, Cynthia Levy, David S Goldberg","doi":"10.1097/HEP.0000000000000961","DOIUrl":"10.1097/HEP.0000000000000961","url":null,"abstract":"<p><strong>Background and aims: </strong>While avoidance of long-term corticosteroids is a common objective in the management of autoimmune hepatitis (AIH), prolonged immunosuppression is usually required to prevent disease progression. This study investigates the patient and provider factors associated with treatment patterns in US patients with AIH.</p><p><strong>Approach and results: </strong>A retrospective cohort of adults with the incident and prevalent AIH was identified from Optum's deidentified Clinformatics Data Mart Database. All patients were followed for at least 2 years, with exposures assessed during the first year and treatment patterns during the second. Patient and provider factors associated with corticosteroid-sparing monotherapy and cumulative prednisone use were identified using multivariable logistic and linear regression, respectively.The cohort was 81.2% female, 66.3% White, 11.3% Black, 11.2% Hispanic, and with a median age of 61 years. Among 2203 patients with ≥1 AIH prescription fill, 83.1% received a single regimen for >6 months of the observation year, which included 52.2% azathioprine monotherapy, 16.9% azathioprine/prednisone, and 13.3% prednisone monotherapy. Budesonide use was uncommon (2.1% combination and 1.9% monotherapy). Hispanic ethnicity (aOR: 0.56; p = 0.006), cirrhosis (aOR: 0.73; p = 0.019), osteoporosis (aOR: 0.54; p =0.001), and top quintile of provider AIH experience (aOR: 0.66; p = 0.005) were independently associated with lower use of corticosteroid-sparing monotherapy. Cumulative prednisone use was greater with diabetes (+441 mg/y; p = 0.004), osteoporosis (+749 mg/y; p < 0.001), and highly experienced providers (+556 mg/y; p < 0.001).</p><p><strong>Conclusions: </strong>Long-term prednisone therapy remains common and unexpectedly higher among patients with comorbidities potentially aggravated by corticosteroids. The greater use of corticosteroid-based therapy with highly experienced providers may reflect more treatment-refractory disease.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"423-435"},"PeriodicalIF":12.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141309768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor: The WHO HDV RNA international standard does not reflect variability of real-world samples. 致编辑的信:世卫组织 HDV RNA 国际标准不能反映真实世界样本的变异性。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-02-01 Epub Date: 2024-06-18 DOI: 10.1097/HEP.0000000000000975
Lisa Sandmann, Birgit Bremer, Katja Deterding, Kerstin Port, Beatrix Gey, Christian Früchtel, André Reinhardt, Ingolf Lachmann, Markus Cornberg, Helenie Kefalakes, Benjamin Maasoumy, Heiner Wedemeyer
{"title":"Letter to the Editor: The WHO HDV RNA international standard does not reflect variability of real-world samples.","authors":"Lisa Sandmann, Birgit Bremer, Katja Deterding, Kerstin Port, Beatrix Gey, Christian Früchtel, André Reinhardt, Ingolf Lachmann, Markus Cornberg, Helenie Kefalakes, Benjamin Maasoumy, Heiner Wedemeyer","doi":"10.1097/HEP.0000000000000975","DOIUrl":"10.1097/HEP.0000000000000975","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"E32-E33"},"PeriodicalIF":12.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141416943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thyroid hormone action and liver disease, a complex interplay. 激素作用与肝病,一种复杂的相互作用。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-02-01 Epub Date: 2023-08-02 DOI: 10.1097/HEP.0000000000000551
Luigi Marino, Adam Kim, Bin Ni, Francesco S Celi
{"title":"Thyroid hormone action and liver disease, a complex interplay.","authors":"Luigi Marino, Adam Kim, Bin Ni, Francesco S Celi","doi":"10.1097/HEP.0000000000000551","DOIUrl":"10.1097/HEP.0000000000000551","url":null,"abstract":"<p><p>Thyroid hormone action is involved in virtually all physiological processes. It is well known that the liver and thyroid are intimately linked, with thyroid hormone playing important roles in de novo lipogenesis, beta-oxidation (fatty acid oxidation), cholesterol metabolism, and carbohydrate metabolism. Clinical and mechanistic research studies have shown that thyroid hormone can be involved in chronic liver diseases, including alcohol-associated or NAFLD and HCC. Thyroid hormone action and synthetic thyroid hormone analogs can exert beneficial actions in terms of lowering lipids, preventing chronic liver disease and as liver anticancer agents. More recently, preclinical and clinical studies have indicated that some analogs of thyroid hormone could also play a role in the treatment of liver disease. These synthetic molecules, thyromimetics, can modulate lipid metabolism, particularly in NAFLD/NASH. In this review, we first summarize the thyroid hormone signaling axis in the context of liver biology, then we describe the changes in thyroid hormone signaling in liver disease and how liver diseases affect the thyroid hormone homeostasis, and finally we discuss the use of thyroid hormone-analog for the treatment of liver disease.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"651-669"},"PeriodicalIF":12.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11737129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10290536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry. 美国 MetALD 患者的候选名单和肝移植:对 UNOS 国家登记处的分析。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-02-01 Epub Date: 2024-04-29 DOI: 10.1097/HEP.0000000000000914
Pedro Ochoa-Allemant, Marina Serper, Roy X Wang, Helen Tang, Bachir Ghandour, Sarem Khan, Nadim Mahmud
{"title":"Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry.","authors":"Pedro Ochoa-Allemant, Marina Serper, Roy X Wang, Helen Tang, Bachir Ghandour, Sarem Khan, Nadim Mahmud","doi":"10.1097/HEP.0000000000000914","DOIUrl":"10.1097/HEP.0000000000000914","url":null,"abstract":"<p><strong>Background and aims: </strong>The new steatotic liver disease (SLD) nomenclature introduced metabolic and alcohol-associated liver disease (MetALD), describing the intersection of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Waitlisting and liver transplantation for MetALD are not well defined. We aimed to develop and validate an algorithm for identifying SLD phenotypes and assessing trends in waitlisting and transplant outcomes.</p><p><strong>Approach and results: </strong>We conducted a retrospective cohort study using the United Network for Organ Sharing registry, supplemented with detailed single-center data. We developed 5 candidate algorithms for SLD classification and calculated their diagnostic performance. Trends in waitlist registrations and transplants were estimated, and competing risk analyses and Cox regression models were conducted to assess waitlist removal and posttransplant outcomes among SLD phenotypes. The best-performing algorithm demonstrated substantial agreement (weighted kappa, 0.62) for SLD phenotypes, with acceptable sensitivity (73%) for MetALD. Between 2002 and 2022, waitlist registrations and transplants for MetALD increased 2.9-fold and 3.3-fold, respectively. Since 2013, there has been a significant increase in the absolute number of waitlist registrations (122 per year; 95% CI, 111-133) and transplants (107 per year; 95% CI, 94-120) for MetALD. Patients with MetALD experienced higher waitlist removal (adjusted subdistribution hazard ratio, 1.10; 95% CI, 1.03-1.17), all-cause mortality (adjusted hazard ratio, 1.13; 95% CI, 1.03-1.23), and graft failure (adjusted hazard ratio, 1.12; 95% CI, 1.03-1.21) than those with alcohol-associated liver disease.</p><p><strong>Conclusions: </strong>We developed and validated an algorithm for identifying SLD phenotypes in UNOS. MetALD is the third leading etiology among those waitlisted and underwent transplantation, exhibiting worse pretransplantation and posttransplantation outcomes compared to alcohol-associated liver disease. Identifying and addressing factors determining poor outcomes is crucial in this patient population.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"532-545"},"PeriodicalIF":12.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment. 在缺乏 RAD51 的肝细胞中,病理多倍体化和细胞衰老的早期发生创造了一种促纤维化和促肿瘤的炎症微环境。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-02-01 Epub Date: 2024-03-11 DOI: 10.1097/HEP.0000000000000821
Wenqing Bu, Xue Sun, Xiaotong Xue, Shengmiao Geng, Tingting Yang, Jia Zhang, Yanan Li, Chao Feng, Qiao Liu, Xiyu Zhang, Peishan Li, Zhaojian Liu, Yufang Shi, Changshun Shao
{"title":"Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.","authors":"Wenqing Bu, Xue Sun, Xiaotong Xue, Shengmiao Geng, Tingting Yang, Jia Zhang, Yanan Li, Chao Feng, Qiao Liu, Xiyu Zhang, Peishan Li, Zhaojian Liu, Yufang Shi, Changshun Shao","doi":"10.1097/HEP.0000000000000821","DOIUrl":"10.1097/HEP.0000000000000821","url":null,"abstract":"<p><strong>Background and aims: </strong>RAD51 recombinase (RAD51) is a highly conserved DNA repair protein and is indispensable for embryonic viability. As a result, the role of RAD51 in liver development and function is unknown. Our aim was to characterize the function of RAD51 in postnatal liver development.</p><p><strong>Approach and results: </strong>RAD51 is highly expressed during liver development and during regeneration following hepatectomy and hepatic injury, and is also elevated in chronic liver diseases. We generated a hepatocyte-specific Rad51 deletion mouse model using Alb -Cre ( Rad51 -conditional knockout (CKO)) and Adeno-associated virus 8-thyroxine-binding globulin-cyclization recombination enzyme to evaluate the function of RAD51 in liver development and regeneration. The phenotype in Rad51 -CKO mice is dependent on CRE dosage, with Rad51fl/fl ; Alb -Cre +/+ manifesting a more severe phenotype than the Rad51fl/fl ; Alb -Cre +/- mice. RAD51 deletion in postnatal hepatocytes results in aborted mitosis and early onset of pathological polyploidization that is associated with oxidative stress and cellular senescence. Remarkable liver fibrosis occurs spontaneously as early as in 3-month-old Rad51fl/fl ; Alb -Cre +/+ mice. While liver regeneration is compromised in Rad51 -CKO mice, they are more tolerant of carbon tetrachloride-induced hepatic injury and resistant to diethylnitrosamine/carbon tetrachloride-induced HCC. A chronic inflammatory microenvironment created by the senescent hepatocytes appears to activate ductular reaction the transdifferentiation of cholangiocytes to hepatocytes. The newly derived RAD51 functional immature hepatocytes proliferate vigorously, acquire increased malignancy, and eventually give rise to HCC.</p><p><strong>Conclusions: </strong>Our results demonstrate a novel function of RAD51 in liver development, homeostasis, and tumorigenesis. The Rad51 -CKO mice represent a unique genetic model for premature liver senescence, fibrosis, and hepatocellular carcinogenesis.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"491-508"},"PeriodicalIF":12.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11737125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140100602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. 用于慢性肝病肝纤维化分期的影像学无创肝病评估:支持 AASLD 实践指南的系统综述。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-02-01 Epub Date: 2024-03-15 DOI: 10.1097/HEP.0000000000000852
Andres Duarte-Rojo, Bachir Taouli, Daniel H Leung, Deborah Levine, Tarek Nayfeh, Bashar Hasan, Yahya Alsawaf, Samer Saadi, Abdul Mounaem Majzoub, Apostolos Manolopoulos, Samir Haffar, Ayca Dundar, M Hassan Murad, Don C Rockey, Mouaz Alsawas, Richard K Sterling
{"title":"Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.","authors":"Andres Duarte-Rojo, Bachir Taouli, Daniel H Leung, Deborah Levine, Tarek Nayfeh, Bashar Hasan, Yahya Alsawaf, Samer Saadi, Abdul Mounaem Majzoub, Apostolos Manolopoulos, Samir Haffar, Ayca Dundar, M Hassan Murad, Don C Rockey, Mouaz Alsawas, Richard K Sterling","doi":"10.1097/HEP.0000000000000852","DOIUrl":"10.1097/HEP.0000000000000852","url":null,"abstract":"<p><strong>Background and aims: </strong>Transient elastography (TE), shear wave elastography, and/or magnetic resonance elastography (MRE), each providing liver stiffness measurement (LSM), are the most studied imaging-based noninvasive liver disease assessment (NILDA) techniques. To support the American Association for the Study of Liver Diseases guidelines on NILDA, we summarized the evidence on the accuracy of these LSM methods to stage liver fibrosis (F).</p><p><strong>Approach and results: </strong>A comprehensive search for studies assessing LSM by TE, shear wave elastography, or MRE for the identification of significant fibrosis (F2-4), advanced fibrosis (F3-4), or cirrhosis (F4), using histopathology as the standard of reference by liver disease etiology in adults or children from inception to April 2022 was performed. We excluded studies with <50 patients with a single disease entity and mixed liver disease etiologies (with the exception of HCV/HIV coinfection). Out of 9447 studies, 240 with 61,193 patients were included in this systematic review. In adults, sensitivities for the identification of F2-4 ranged from 51% to 95%, for F3-4 from 70% to 100%, and for F4 from 60% to 100% across all techniques/diseases, whereas specificities ranged from 36% to 100%, 74% to 100%, and 67% to 99%, respectively. The largest body of evidence available was for TE; MRE appeared to be the most accurate method. Imaging-based NILDA outperformed blood-based NILDA in most comparisons, particularly for the identification of F3-4/F4. In the pediatric population, imaging-based NILDA is likely as accurate as in adults.</p><p><strong>Conclusions: </strong>LSM from TE, shear wave elastography, and MRE shows acceptable to outstanding accuracy for the detection of liver fibrosis across various liver disease etiologies. Accuracy increased from F2-4 to F3-4 and was the highest for F4. Further research is needed to better standardize the use of imaging-based NILDA, particularly in pediatric liver diseases.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"725-748"},"PeriodicalIF":12.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140136301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PSC and colitis: A complex relationship
IF 13.5 1区 医学
Hepatology Pub Date : 2025-01-22 DOI: 10.1097/hep.0000000000001236
Ludwig J. Horst, Jan Kempski, Martine Walmsley, Samuel Huber, Christoph Schramm
{"title":"PSC and colitis: A complex relationship","authors":"Ludwig J. Horst, Jan Kempski, Martine Walmsley, Samuel Huber, Christoph Schramm","doi":"10.1097/hep.0000000000001236","DOIUrl":"https://doi.org/10.1097/hep.0000000000001236","url":null,"abstract":"Primary sclerosing cholangitis is one of the most challenging conditions in hepatology, and due to our limited understanding of its pathogenesis, no causal therapies are currently available. While it was long assumed that a minority of people with IBD also develop PSC, which is sometimes labeled an extraintestinal manifestation of IBD, the clinical phenotype, genetic and intestinal microbiota associations strongly argue for PSC-IBD being a distinct form of IBD, existing alongside ulcerative colitis and Crohn’s disease. In fact, the liver itself could contribute to intestinal pathology, clinically overt in 60 – 80 % of patients. Recent studies suggested that on a molecular level, almost all people with PSC have underlying colitis. The extent to which the liver and gut influence each other clinically and in terms of disease progression has not yet been conclusively revealed. However, while it seemed intuitive that the two diseases have a negative influence on each other, evidence suggests that sclerosing cholangitis can also be protective for the gut and that colitis can in certain settings ameliorate liver pathology. This underscores the complex pathophysiological relationships, where factors such as genetic predisposition, changes in the intestinal microbiota, altered bile acid metabolism, and immune cell migration are among the suspected contributors. PSC is an emerging disease with a significant impact on health-related quality of life of affected people. With this review, we aim to summarize the current knowledge on the gut-liver axis in PSC-IBD, provide new perspectives on risk stratification and treatment and identify gaps in our current knowledge. Our understanding of this complex relationship will therefore help to design clinical trials and shape the future therapy of PSC-IBD.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"17 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143020361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the immune landscape of IDH1-mutant cholangiocarcinoma: Pathways to new therapies
IF 13.5 1区 医学
Hepatology Pub Date : 2025-01-21 DOI: 10.1097/hep.0000000000001241
Binbin Li, Sumera I. Ilyas
{"title":"Unveiling the immune landscape of IDH1-mutant cholangiocarcinoma: Pathways to new therapies","authors":"Binbin Li, Sumera I. Ilyas","doi":"10.1097/hep.0000000000001241","DOIUrl":"https://doi.org/10.1097/hep.0000000000001241","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"32 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142992109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of LRP4 mutations on hepatocellular carcinoma recurrence and immunotherapy response
IF 13.5 1区 医学
Hepatology Pub Date : 2025-01-16 DOI: 10.1097/hep.0000000000001235
Zhen Lu, Chun-Ming Wong
{"title":"The impact of LRP4 mutations on hepatocellular carcinoma recurrence and immunotherapy response","authors":"Zhen Lu, Chun-Ming Wong","doi":"10.1097/hep.0000000000001235","DOIUrl":"https://doi.org/10.1097/hep.0000000000001235","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"17 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142986373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening
IF 13.5 1区 医学
Hepatology Pub Date : 2025-01-16 DOI: 10.1097/hep.0000000000001181
Guneet Sidhu
{"title":"Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening","authors":"Guneet Sidhu","doi":"10.1097/hep.0000000000001181","DOIUrl":"https://doi.org/10.1097/hep.0000000000001181","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"3 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142986370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信